IL13RA2 and glioblastoma: A case study of a patient with recurrent multifocal glioblastoma who was given multiple infusions of CAR T-cells engineered to target interleukin-13 receptor alpha 2 (IL13Rα2) showed good tolerance and regression of intracranial and spinal tumours [111].